GeoVax Labs, Inc. (OTCQB: GOVX) is a clinical-stage biotechnology company developing innovative human vaccines using our novel DNA/MVA platform technology. The company’s primary focus has been to develop vaccines that prevent and fight Human Immunodeficiency Virus (HIV) infections. Uncontrolled HIV infections result in Acquired Immunodeficiency Syndrome (AIDS). GeoVax also recently initiated a new program for the development of a vaccine to prevent Ebola infection. The company’s vaccine technology was developed in collaboration with researchers at Emory University, the NIH, and the CDC. The technology developed by the collaboration is exclusively licensed to us from Emory University. GeoVax also has nonexclusive licenses to certain patents owned by the NIH. All of the human clinical trials of the company’s preventive vaccines to date have been conducted by the HIV Vaccine Trials Network (HVTN) with funding from the National Institute of Allergy and Infectious Disease (NIAID) of the National Institutes of Health (NIH). SNNLive spoke with Robert McNally, Ph.D., President and CEO of GeoVax Labs, Inc. at the Healthcare Media Day 2015 in San Francisco, CA.
Dr. McNally begins with an overview of the company, “We’re a clinical-stage biotech formed in 2001, we actually are a spin-out from Emory University in Atlanta so that’s our home base.” He continues with what’s currently going on in the company, “We’ve got a couple of interesting things going on. The first one is in the HIV/AIDS vaccine space. We’re the first vaccine to graduate out of the Emory University vaccine program and we’ve progressed to the point now where our vaccine for North America, the version of HIV for North America, we’re leading – we’re actually the leading vaccine candidate, next one poised to eventually get into phase 2b efficacy trials, which in HIV is really rare. And then the second point is really with Ebola, so we’ve segued from using our vaccine constructs to applying to this particular epidemic and actually strategizing ourselves to be like a second-generation vaccine for Ebola.”
He continues, “We’re really poised to come out into clinicals in 2016, so it’ll be there roughly the second half of 2016. It takes a while to produce a vaccine, the interesting thing about this is that vaccines take time and the ones that they’re dusting off the shelf are there basically in desperation, they’ve been on the shelf for a number of years, didn’t really have an epidemic to go out there and do a test with them and so hurriedly they’re getting out there…and we’re using sequences that are up to date to this particular epidemic plus the other two versions of Ebola.” For more information, check out their website: www.GeoVax.com
© 2017 Stock News Now
Supported by Superior Web Solutions